seletalisib   Click here for help

GtoPdb Ligand ID: 9800

Synonyms: UCB 5857 | UCB-5857 | UCB5857
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Seletalisib is an orally bioavailable, potent and selective, ATP-competitive, small molecule inhibitor of PI3Kδ that is being developed by UCB Pharma for the treatment of immune and inflammatory diseases [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 90.53
Molecular weight 482.09
XLogP 5.6
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES [O-][n+]1cccc(c1)c1nc2c(cc1C(C(F)(F)F)Nc1ncnc3c1nccc3)cccc2Cl
Isomeric SMILES [O-][n+]1cccc(c1)c1nc2c(cc1[C@H](C(F)(F)F)Nc1ncnc3c1nccc3)cccc2Cl
InChI InChI=1S/C23H14ClF3N6O/c24-16-6-1-4-13-10-15(18(31-19(13)16)14-5-3-9-33(34)11-14)21(23(25,26)27)32-22-20-17(29-12-30-22)7-2-8-28-20/h1-12,21H,(H,29,30,32)/t21-/m1/s1
Immunopharmacology Comments
Seletalisib is a selective PI3Kδ inhibitor that is being developed for the treatment of immune and inflammatory diseases [1].
Immunopharmacology Disease
Disease X-Refs Comment References
Psoriasis Disease Ontology: DOID:8893
Phase 1 clinical candidate for psoriasis- see NCT02303509 2
Sjögren's syndrome Orphanet: ORPHA378
Phase 2 clinical candidate for primary SS, but trial NCT02610543 was terminated as they struggled to recruit patients.